Gland Pharma Limited
GLAND
Peringkat dalam Saham
#3304
Gland Pharma Limited, established in Hyderabad, India, in 1978, is a... Gland Pharma Limited, established in Hyderabad, India, in 1978, is a pharmaceutical company that specializes in the creation, production, and global distribution of generic injectable medications. Its product line features key active pharmaceutical ingredients such as heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections, among others. The company's extensive therapeutic portfolio encompasses anti-infectives, anesthetics, anticoagulants, antimalarials, cardiovascular drugs, gastrointestinal treatments, pain management, hormones, fertility aids, anti-cancer agents, gynecological remedies, neurological and central nervous system medications, respiratory treatments, blood-related products, ophthalmological and otological solutions, orthopedics, hematinics, and various vitamins, minerals, and nutrients. Additionally, Gland Pharma provides contract development services. The company primarily operates on a business-to-business (B2B) model, distributing its products across major markets including the United States, Europe, Canada, Australia, India, and other international territories. Gland Pharma Limited functions as a subsidiary of Fosun Pharma Industrial Pte. Ltd.
Harga Saham
$32.32
Kapitalisasi Pasar
$5.33B
Perubahan (1 hari)
-3.01%
Perubahan (1 tahun)
47.99%
Negara
IN
Perdagangan Gland Pharma Limited (GLAND)
Kategori
Healthcare
Laba untuk Gland Pharma Limited (GLAND)
Laba pada Jun 2026 TTM: $175.12M
Menurut laporan keuangan terbaru dari Gland Pharma Limited, laba saat ini perusahaan adalah $175.12M. Pada tahun 2024, perusahaan memperoleh laba sebesar $135.82M, peningkatan dibandingkan laba tahun 2023 sebesar $128.32M. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Gland Pharma Limited dari 2017 hingga 2026
Laba pada akhir setiap tahun
| Tahun | Laba | Mengubah |
|---|---|---|
| 2026 (TTM) | $175.12M | 40.94% |
| 2025 | $124.25M | -8.52% |
| 2024 | $135.82M | 5.84% |
| 2023 | $128.32M | -39.82% |
| 2022 | $213.22M | 16.94% |
| 2021 | $182.34M | 38.35% |
| 2020 | $131.79M | 33.35% |
| 2019 | $98.83M | 28.32% |
| 2018 | $77.02M | -13.59% |
| 2017 | $89.13M | 0.00% |
Laba untuk perusahaan serupa atau pesaing
| Perusahaan | Laba | Perbedaan Laba | Negara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 907.63% |
IN
|
